A new analysis of the EMPA-TROPISM trial found the sodium-glucose cotransporter-2 (SGLT2) receptor inhibitor empagliflozin significantly improved adiposity, interstitial myocardial fibrosis, aortic stiffness, and inflammatory markers in nondiabetic patients with heart failure with reduced ejection fraction (HFrEF).